PDF(Pubmed)
Abstract：
BACKGROUND: Non-metastatic castration-resistant prostate cancer (nmCRPC) is an asymptomatic condition with the potential to progress to metastasis. Novel hormonal agents (NHAs) are currently considered the gold standard treatment for nmCRPC, offering significant survival benefits. However, further evidence is needed to determine whether there are differences in the performance of these drugs among Asian populations.
METHODS: This retrospective analysis of nmCRPC patients aims to compare the efficacy and safety of three NHAs-apalutamide, darolutamide, and enzalutamide. Data were collected from two prominent prostate care centers in Taichung, Taiwan. Patient characteristics, treatment details, PSA responses, and adverse events were analyzed. Statistical comparisons were performed, and the study received Institutional Review Board approval.
RESULTS: Total of 64 patients were recruited in this study, including 29 darolutamide, 26 apalutamide, and 9 enzalutamide patients. Baseline characteristics varied between the three patient groups, but the treatment response still revealed similar results. The apalutamide group experienced more adverse events, notably skin rash. Discontinuation rates due to adverse events differed among the groups, and patients receiving darolutamide were less likely to discontinue treatment.
CONCLUSIONS: This real-world study provides insights into NHA utilization in nmCRPC within the Taiwanese population. Adverse event profiles varied, emphasizing the need for individualized treatment decisions. The study underscores the importance of regional considerations and contributes valuable data for optimizing treatment outcomes in nmCRPC.
METHODS: This retrospective analysis of nmCRPC patients aims to compare the efficacy and safety of three NHAs-apalutamide, darolutamide, and enzalutamide. Data were collected from two prominent prostate care centers in Taichung, Taiwan. Patient characteristics, treatment details, PSA responses, and adverse events were analyzed. Statistical comparisons were performed, and the study received Institutional Review Board approval.
RESULTS: Total of 64 patients were recruited in this study, including 29 darolutamide, 26 apalutamide, and 9 enzalutamide patients. Baseline characteristics varied between the three patient groups, but the treatment response still revealed similar results. The apalutamide group experienced more adverse events, notably skin rash. Discontinuation rates due to adverse events differed among the groups, and patients receiving darolutamide were less likely to discontinue treatment.
CONCLUSIONS: This real-world study provides insights into NHA utilization in nmCRPC within the Taiwanese population. Adverse event profiles varied, emphasizing the need for individualized treatment decisions. The study underscores the importance of regional considerations and contributes valuable data for optimizing treatment outcomes in nmCRPC.
摘要：
背景：非转移性去势抵抗性前列腺癌（nmCRPC）是一种无症状的疾病，有可能发展为转移。新型激素剂（NHA）目前被认为是nmCRPC的黄金标准治疗，提供显著的生存益处。然而,需要进一步的证据来确定这些药物在亚洲人群中的性能是否存在差异.
方法：这项对nmCRPC患者的回顾性分析旨在比较三种NHA-阿帕鲁胺的疗效和安全性，达鲁柳胺,和恩扎鲁他胺.数据来自台中两个著名的前列腺护理中心，台湾。患者特征,治疗细节,PSA反应,并对不良事件进行分析。进行了统计比较，该研究获得了机构审查委员会的批准。
结果：本研究共招募了64名患者，包括29个达鲁他胺,26阿帕鲁胺，和9名恩杂鲁胺患者。三组患者的基线特征不同，但是治疗反应仍然显示出类似的结果。阿帕鲁胺组出现了更多的不良事件，尤其是皮疹。由于不良事件导致的停药率在各组之间存在差异，接受达洛鲁胺的患者停止治疗的可能性较小.
结论：这项现实世界的研究提供了对台湾人口中nmCRPC中NHA利用的见解。不良事件概况各不相同，强调个性化治疗决策的必要性。该研究强调了区域考虑因素的重要性，并为优化nmCRPC的治疗结果提供了有价值的数据。
方法：这项对nmCRPC患者的回顾性分析旨在比较三种NHA-阿帕鲁胺的疗效和安全性，达鲁柳胺,和恩扎鲁他胺.数据来自台中两个著名的前列腺护理中心，台湾。患者特征,治疗细节,PSA反应,并对不良事件进行分析。进行了统计比较，该研究获得了机构审查委员会的批准。
结果：本研究共招募了64名患者，包括29个达鲁他胺,26阿帕鲁胺，和9名恩杂鲁胺患者。三组患者的基线特征不同，但是治疗反应仍然显示出类似的结果。阿帕鲁胺组出现了更多的不良事件，尤其是皮疹。由于不良事件导致的停药率在各组之间存在差异，接受达洛鲁胺的患者停止治疗的可能性较小.
结论：这项现实世界的研究提供了对台湾人口中nmCRPC中NHA利用的见解。不良事件概况各不相同，强调个性化治疗决策的必要性。该研究强调了区域考虑因素的重要性，并为优化nmCRPC的治疗结果提供了有价值的数据。
